Lipid-Lowering, Honestly

Few topics in medicine are argued about more online and misunderstood more completely than statins. This page lays out what the trials actually show — the per-mmol/L rule, why absolute risk decides everything, what the side-effect evidence really says, and what each drug class added. It describes evidence; it does not prescribe. Medication decisions are clinician territory, and this page is preparation for that conversation, not a replacement for it.

The Rule the Trials Agree On

The Cholesterol Treatment Trialists' meta-analysis of 26 trials and about 170,000 participants found that each 1 mmol/L (~39 mg/dL) reduction in LDL-C lowered major vascular events by roughly 21% (CTT Collaboration, The Lancet, 2010) — with the curves separating within the first year or two and widening for as long as treatment continues. The genetic version of the same experiment is more striking: people born with naturally lower LDL enjoy a much larger per-mmol/L protection, about two and a half times the trial benefit, because the exposure lasts a lifetime (Ference et al., JACC, 2012). That asymmetry — lower, earlier, and longer wins — is the most durable insight in lipid science: it explains why a 40-year-old's borderline LDL deserves attention even when an identical number at 70 draws less, and why decades of modest lowering beat a few intense years late in the game. Post-trial follow-ups point the same direction: the benefit of years on a statin appears to persist after stopping — a legacy pattern consistent with exposure time, not just current level, being what builds protection.

Absolute Risk Is the Whole Game

The real question is not "is my LDL high?" but "what is my absolute risk, and how much does therapy move it?" Two cases with identical LDL-C readings make the point:

Person B's "better" LDL carries the bigger problem — which is why risk-estimator tools exist and why clinicians compute instead of intuiting. The honest bottom line: for established disease or high calculated risk, statin benefit is among the most thoroughly documented in medicine; for young, low-risk people, the absolute benefit is real but small, and either choice is defensible — which is exactly why this decision belongs in a clinic, not a comment section.

The Side-Effect Ledger, Read Honestly

• 💪 Muscle symptoms. Real in some people, but the placebo-controlled picture is humbling. In the SAMSON n-of-1 trial, 60 people who had stopped statins for muscle symptoms took statin and placebo in blinded alternation: 90% of the symptom burden they attributed to the statin also occurred on placebo (Wood et al., NEJM, 2020). The ASCOT-LLA trial found no excess muscle symptoms in its blinded phase, while its open-label extension produced abundant reports (Gupta et al., The Lancet, 2017) — textbook nocebo.
• 🍬 New diabetes. Statins carry a modest, real increase — about 9% relative, concentrated in people already near the diagnostic threshold (Sattar et al., The Lancet, 2010). For high-risk people the event reduction dwarfs it; for low-risk people it is one more reason to weigh absolute benefit.
• 🧠 Cognition. Randomized evidence does not support dementia risk, and the rare reversible memory complaints reported in case series don't hold up in trial data (Collins et al., The Lancet, 2016).
• 🛑 Severe harms. Rhabdomyolysis is rare — roughly four extra cases per 10,000 people treated for five years in the meta-analysis — and concentrates with high doses and interacting drugs.
• 🩺 Liver enzymes. Mild transaminase elevations are common and usually settle without stopping therapy; clinically significant liver injury from statins is rare enough that routine monitoring is no longer recommended by US regulators — an extra test with little yield.

Beyond Statins: The Ledger

When statins are not enough, or not tolerated, the modern toolkit is deeper than most people realize. Ezetimibe added a small but real benefit on top of statins in IMPROVE-IT (Cannon et al., NEJM, 2015). The PCSK9 inhibitors evolocumab and alirocumab each reduced events by about 15% in high-risk patients already on statins (Sabatine et al., NEJM, 2017; Schwartz et al., NEJM, 2018). Bempedoic acid reduced events in statin-intolerant patients (Nissen et al., NEJM, 2023). And niacin — for decades a reflex prescription — failed to reduce events and added harms, ending that era. The table condenses the ledger:

The Honest Order of Operations

• 🥗 Lifestyle first, measured. Soluble fiber, fat swaps, and weight loss move LDL/ApoB modestly but meaningfully — fiber and fat swaps have their own topics, and the Quarterly Audit protocol covers retesting after three months of honest effort. Measure before you medicate — the panel arbitrates whether the lifestyle response was enough.
• 🏥 Absolute risk decides the rest. Established disease or high calculated risk moves the question into medication territory, with your clinician.
• 💊 Generic statin first. An extraordinary amount of outcome evidence per dollar; titration beats switching when tolerated.
• ➕ Ezetimibe second. Cheap, well-tolerated, proven as an add-on.
• 💉 PCSK9 inhibitors for residual high risk. The biggest additional reductions, at a real cost.
• 🔁 Bempedoic acid for the truly statin-intolerant. A newer option with outcome data in exactly that population.
• 🌿 Plant sterols and stanols: real but modest — single-digit to roughly 10% LDL reduction at 2 g/day — an adjunct, not a substitute.
• ❌ What not to chase: HDL-raising drugs (a failed era the parent topic covers), niacin, and supplement-aisle "cholesterol support" with no outcome data behind it.

Statin Questions, Answered Briefly

• 💪 Will I get muscle pain? Maybe — but in blinded trials, most people who report statin muscle symptoms report the same on placebo. Genuine statin-associated symptoms exist and usually respond to dose reduction, switching, or an alternative class.
• 🧠 Do statins cause dementia? Randomized evidence does not support it, and the small reversible memory reports don't reproduce in trials.
• 🍬 What about diabetes? A real but modest increase — about 9% relative, concentrated near the diagnostic threshold — weighed against the event reduction in people who need therapy.
• ⏱️ How long until benefits show? Event curves separate within one to two years and widen for as long as treatment continues; the genetic evidence says decades of modest lowering beat a few intense years.
• 🌿 Is red yeast rice a "natural statin"? Literally — it contains monacolin K, the same molecule as lovastatin, in unstandardized doses. It is a statin with worse quality control, not an alternative to one.
• 🛑 Can I stop once LDL is low? The benefit is exposure-dependent — stopping returns risk toward baseline over time. That is a clinician conversation, not a solo call.
• 🐟 What about fibrates and fish oil? Those are triglyceride conversations, not LDL ones — the triglycerides page has the trial ledger, and the short version is that most of it came back neutral.

Related Topics